<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="535">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05154188</url>
  </required_header>
  <id_info>
    <org_study_id>CIP25</org_study_id>
    <nct_id>NCT05154188</nct_id>
  </id_info>
  <brief_title>Post Approval Study to Assure the ContInued saFety and effectIveness of Neuro Cochlear Implant System in Adult Users</brief_title>
  <acronym>PACIFIC</acronym>
  <official_title>Post Approval Study to Assure the ContInued saFety and effectIveness of Neuro Cochlear Implant System in Adult Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oticon Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oticon Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      On June 23, 2021, the Oticon Medical Neuro Cochlear Implant System (NCIS) was granted&#xD;
      premarket approval (PMA) in the US to treat individuals 18 years or older, with bilateral&#xD;
      severe-to-profound sensorineural hearing loss, who obtain limited benefit from appropriately&#xD;
      fitted hearing aid(s).&#xD;
&#xD;
      To help assure the continued safety and effectiveness of an approved device, a post-approval&#xD;
      study was required as a condition of approval under 21 CFR 814.82(a)(2).&#xD;
&#xD;
      The purpose of this study is to provide longer-term data on the safety and effectiveness of&#xD;
      the Neuro Cochlear Implant System under general conditions of use in the postmarket&#xD;
      environment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The post-approval study will be an open-label, prospective, multi-center, single-arm,&#xD;
      non-randomized, self-controlled clinical trial in 10 clinical sites in the US.&#xD;
&#xD;
      The purpose of this study is to provide longer-term data on the safety and effectiveness of&#xD;
      the Neuro Cochlear Implant System under general conditions of use in the postmarket&#xD;
      environment. This study will be conducted as a prospective, non-controlled, non-randomized&#xD;
      study in 10 clinical sites.&#xD;
&#xD;
      A total of 60 subjects, newly treated will be enrolled. Study subjects will be followed for 3&#xD;
      years post implantation of the device with a target follow-up rate of 80% at the end of the&#xD;
      study&#xD;
&#xD;
      The primary safety endpoint is the comparison of the type and frequency of adverse events and&#xD;
      serious adverse events observed during the study period. The effectiveness endpoints will&#xD;
      include the within-subject differences for sentence recognition as evaluated with the AzBio&#xD;
      test.&#xD;
&#xD;
      The study will include the following visits: baseline, 1-month post-surgery (activation&#xD;
      date), 3 months, 6-months, 12-months, 18-months, 24-months, and 36-months post-activation.&#xD;
      Each participant will serve as their own control with baseline measurements.&#xD;
&#xD;
      The total estimated duration of the study is 60 months: 24 months of recruitment and 36&#xD;
      months of subject participation.&#xD;
&#xD;
      The first patient is expected to be included within 6 months of study approval (obtained on&#xD;
      August 19, 2021).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 19, 2022</start_date>
  <completion_date type="Anticipated">February 2027</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stability of improvement of speech perception performance at 12- and 36-months post-activation with AzBio sentence scores.</measure>
    <time_frame>At 12- and 36-months post-activation (visit 9 and visit 11)</time_frame>
    <description>Average scores for AzBio sentence tests will be recorded in Quiet at 12- and 36-months post-activation and compared to pre-operative (baseline) measures.&#xD;
The AzBio sentence test is a validated sentence recognition test in quiet and has a score range of 0-100% with higher values indicating better scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety outcome</measure>
    <time_frame>From Visit 1(8- 12 weeks pre-surgery) to Visit 12 (36 Months post-activation)</time_frame>
    <description>Occurrence and severity of all adverse events and serious adverse events occuring during the study period. All device failures (internal and external parts) will be documented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stability of improvement of speech perception performance at 12- and 36-months post-activation with CNC-words scores.</measure>
    <time_frame>At 12- and 36-months post-activation (visit 9 &amp; visit 12)</time_frame>
    <description>Consonant-Nucleus-Consonant (CNC) scores will be recorded in Quiet at 12- and 36-months post-activation and compared to pre-operative (baseline) measures.&#xD;
The CNC word test has a score range of 0-100% with higher values indicating better scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability of outcomes over time using AzBio Sentence scores at 1 month in Quiet.</measure>
    <time_frame>At 1 month post-activation (Visit 6)</time_frame>
    <description>Scores for AzBio sentence tests will be recorded in Quiet at 1-month post-activation in quiet and compared to pre-operative (baseline) measures.&#xD;
The AzBio sentence test is a validated sentence recognition test in quiet and has a score range of 0-100% with higher values indicating better scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability of outcomes over time using AzBio sentences in Quiet and Noise at 3- ; 6- and 24-months post-activation</measure>
    <time_frame>at 3 months(visit 7), 6 months (visit 9) and 24 months (visit 11)</time_frame>
    <description>Average scores for AzBio sentence tests will be recorded in Quiet at 3- ; 6- and 24-months post-activation and compared to pre-operative (baseline) measures.&#xD;
The AzBio sentence test is a validated sentence recognition test and has a score range of 0-100% with higher values indicating better scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability of outcomes over time using CNC word scores at 3-, 6- and 24-months</measure>
    <time_frame>At 3 months(visit 7), 6 months (visit 9) and 24 months (visit 11)</time_frame>
    <description>Average scores for CNC word test will be recorded at 3-, 6- and 24 months post-activation and compared to pre-operative (baseline) measures.&#xD;
The Consonant-Nucleus-Consonant (CNC) word test has a score range of 0-100% with higher values indicating better scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability of outcomes over time for patients under a bimodal condition (i.e., patient wearing a contralateral hearing aid).</measure>
    <time_frame>At 3-months post activation (visit 7) and 12 months (visit 9)</time_frame>
    <description>Average scores for AzBio sentence tests will be recorded in Noise (at +10dB SNR), at 3- and 12-months post-activation and compared to pre-operative (baseline) measures.&#xD;
The AzBio sentence test is a validated sentence recognition test and has a score range of 0-100% with higher values indicating better scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal measures of patient reported outcomes in a newly-implanted population</measure>
    <time_frame>At 6-,12-,24- and 36 months post-activation (Visits 8,9,11,12)</time_frame>
    <description>Patient reported outcome (PRO) measures including quality of life, listening effort and tinnitus at 6-,12-,24- and 36 months post-activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal measures of cognitive abilities in a newly implanted population</measure>
    <time_frame>At 12-24 and 36 months post-activation (Visits 9,11,12)</time_frame>
    <description>Scores on a cognitive assessment at 12-24 and 36 months post-activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal programming parameters (T- and C- levels)</measure>
    <time_frame>At activation (Visit 5), then from 3 months post-activation (V7) throught study completion (an average of 3 years post activation)</time_frame>
    <description>T and C levels collected at all intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal device functionality measures (impedances)</measure>
    <time_frame>At activation (Visit 5), then from 3 months post-activation (V7) throught study completion (an average of 3 years post activation)</time_frame>
    <description>Electrode impedances collected at all intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pedictors of outcomes: Electrode impedances collected at all intervals</measure>
    <time_frame>At surgery visit (Visit 3 baseline visit) then from activation, 1-month post surgery( visit 5) throught study completion (an average of 3 years post activation)</time_frame>
    <description>Electrode impedances collected at all intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pedictors of outcomes: eCAP responses collected in the operating room</measure>
    <time_frame>From activation (visit 5) throught study completion (an average of 3 years post activation)</time_frame>
    <description>eCAP responses collected in the operating room</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of major postsurgical complications and AEs over time</measure>
    <time_frame>At surgery visit (i.e. visit 3, baseline visit, )</time_frame>
    <description>Surgeon perception of handling of the Neuro Zti and electrode array as well as information related to surgical technique</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sensorineural Hearing Loss, Bilateral</condition>
  <condition>Sensorineural Hearing Loss, Severe</condition>
  <condition>Sensorineural Hearing Loss, Profound</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neuro Cochlear Implant system</intervention_name>
    <description>Patients will be regular candidates for a cochlear implantation surgery, according to the indication criteria of the Neuro Cochlear Implant System and the device will be used according to its intended purpose</description>
    <other_name>Neuro ZtiCLA implant</other_name>
    <other_name>Neuro ZtiEVO implant</other_name>
    <other_name>Neuro 2 Sound Processor</other_name>
    <other_name>Neuro 2 SP</other_name>
    <other_name>Neuro Zti</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  The current post-approval study concerning the NCIS will enroll a total of 60&#xD;
             subjects, newly treated. Patients will be regular candidates for a cochlear&#xD;
             implantation surgery, according to the indication criteria of the Neuro Cochlear&#xD;
             Implant System and the device will be used according to its intended purpose.&#xD;
&#xD;
          -  60 subjects must meet the eligibility criteria&#xD;
&#xD;
          -  The patient can be an existing audiology patient of the CI clinic or can be referred&#xD;
             from an outside hearing aid clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals 18 years of age or older&#xD;
&#xD;
          -  Obtain limited benefit from appropriately fitted hearing aids&#xD;
&#xD;
          -  Bilateral severe-to-profound sensorineural hearing loss _ Severe-to-profound hearing&#xD;
             loss is determined by a pure-tone average (PTA) superior or equal (â‰¥) to 70 dB HL at&#xD;
             500, 1000 and 2000 Hz. Limited benefit from amplification is defined by scores of 50%&#xD;
             or less on a validated sentence recognition test in quiet (AzBio sentences), in the&#xD;
             best-aided listening condition _&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous cochlear implantation&#xD;
&#xD;
          -  Ossification or any other cochlear anomaly that might prevent complete insertion of&#xD;
             the electrode array&#xD;
&#xD;
          -  Active external or middle ear infections or tympanic membrane perforation in the ear&#xD;
             to be implanted&#xD;
&#xD;
          -  Presence of medical contraindications to middle-ear or inner-ear surgery or anesthesia&#xD;
             as required&#xD;
&#xD;
          -  Diagnosis of retro-cochlear pathology&#xD;
&#xD;
          -  Diagnosis of auditory neuropathy&#xD;
&#xD;
          -  Unrealistic expectations on the part of the subject regarding the possible benefits,&#xD;
             risks, and limitations that are inherent to the surgical procedure and use of the&#xD;
             prosthetic device&#xD;
&#xD;
          -  Unwillingness or inability to comply with all investigational requirements&#xD;
&#xD;
          -  Additional cognitive, medical, or social handicaps that would prevent completion of&#xD;
             all study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michel HOEN, PHD</last_name>
    <phone>+33679191047</phone>
    <email>MHOE@oticonmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Phil Segel, PHD</last_name>
    <phone>+1 908 200 1751 (mobile)</phone>
    <email>phsg@oticonmedical.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>candidates for a cochlear implantation surgery</keyword>
  <keyword>patients aged 18 years and older</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
    <mesh_term>Hearing Loss, Bilateral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

